Stoke Therapeutics (STOK) Shares Outstanding (2018 - 2026)

Stoke Therapeutics' Shares Outstanding history runs 9 years deep, the most recent figure standing at $62.2 million for Q1 2026.

• In Q1 2026, Shares Outstanding rose 14.0% year-over-year to $62.2 million; the TTM figure through Mar 2026 stood at $62.2 million (up 14.0% YoY), while the FY2025 annual figure was $58.9 million, up 9.05% from the prior year.
• Shares Outstanding was $62.2 million for Q1 2026 at Stoke Therapeutics, up from $58.9 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $62.2 million in Q1 2026 to a low of $39.0 million in Q1 2022.
• Historically, Shares Outstanding has averaged $48.7 million across 5 years, with a median of $46.5 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding grew 19.52% in 2024, then grew 4.12% in 2025.
• A 5-year view of Shares Outstanding shows it stood at $39.4 million in 2022, then rose by 16.43% to $45.9 million in 2023, then gained by 17.67% to $54.0 million in 2024, then climbed by 9.05% to $58.9 million in 2025, then grew by 5.63% to $62.2 million in 2026.
• The last three Shares Outstanding figures came in at $62.2 million (Q1 2026), $58.9 million (Q4 2025), and $55.1 million (Q3 2025), per Business Quant data.